Production Method 1

13939-06-5

166526-03-0

1060802-59-6

89284-61-7

100-54-9

Reaction Conditions

1.1 Solvents: Acetonitrile ,  Water ;  16 h, pH 9.5, rt → 45 °C
1.2 Reagents: Sodium chloride Solvents: Ethanol ;  overnight, -20 °C
1.3 Reagents: Cesium hydroxide Catalysts: Palladate(1-), [2′-(amino-κN)[1,1′-biphenyl]-2-yl-κC]chloro[2′-(dicyclohexylphos… Solvents: 1-Methoxy-2-propanol ,  Water ;  15 h, 80 °C

Reference

Palladium-Catalyzed Hydroxycarbonylation of (Hetero)aryl Halides for DNA-Encoded Chemical Library Synthesis

Li, Jian-Yuan; Miklossy, Gabriella; Modukuri, Ram K.; Bohren, Kurt M.; Yu, Zhifeng; et al, Bioconjugate Chemistry, 2019, 30(8), 2209-2215

3-cyanopyridine-4-carboxylic acid Raw materials

• Hexacarbonylmolybdenum
• 4,6-Dichloronicotinonitrile

3-cyanopyridine-4-carboxylic acid Preparation Products

• 3-cyanopyridine-4-carboxylic acid (1060802-59-6)
• 4-chloropyridine-3-carbonitrile (89284-61-7)
• pyridine-3-carbonitrile (100-54-9)

• 1. An automatic determination of thoria in thoria-urania mixtures
  Analyst, 1966,91, 208-210
• 2. An atomistic mechanism for the degradation of perovskite solar cells by trapped charge?
  Eunhak Lim,Jiyoung Heo,Seong Keun Kim Nanoscale, 2019,11, 11369-11378
• 3. An integrated process of CO2 capture and in situ hydrogenation to formate using a tunable ethoxyl-functionalized amidine and Rh/bisphosphine system?
  Yu-Nong Li,Liang-Nian He,Xian-Dong Lang,Xiao-Fang Liu,Shuai Zhang RSC Adv., 2014,4, 49995-50002
• 4. An astrophysically-relevant mechanism for amino acid enantiomer enrichment
  Stephen P. Fletcher,Richard B. C. Jagt,Ben L. Feringa Chem. Commun., 2007, 2578-2580
• 5. An apparatus for testing water by measurement of its electrical conductivity
  Analyst, 1912,37, 538-543

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyridines and derivatives Pyridinecarboxylic acids
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyridines and derivatives Pyridinecarboxylic acids and derivatives Pyridinecarboxylic acids

Recent Advances in the Application of 3-Cyanopyridine-4-Carboxylic Acid (CAS: 1060802-59-6) in Chemical Biology and Pharmaceutical Research

3-Cyanopyridine-4-carboxylic acid (CAS: 1060802-59-6) has emerged as a versatile scaffold in medicinal chemistry and chemical biology research due to its unique structural features and diverse pharmacological potential. Recent studies have highlighted its significance as a key intermediate in the synthesis of bioactive molecules and its direct role as a pharmacophore in drug discovery programs. This research brief synthesizes the latest findings on this compound, focusing on its synthetic applications, biological activities, and therapeutic implications.

Structural analysis reveals that 3-cyanopyridine-4-carboxylic acid combines both hydrogen bond donor/acceptor capabilities through its carboxylic acid group and π-deficient character from the cyanopyridine moiety. This dual functionality enables its participation in various molecular interactions, making it particularly valuable for designing enzyme inhibitors and receptor modulators. Recent computational studies published in the Journal of Medicinal Chemistry (2023) have demonstrated its optimal physicochemical properties for blood-brain barrier penetration, suggesting potential CNS applications.

In synthetic chemistry, 1060802-59-6 has shown remarkable utility as a building block for heterocyclic compounds. A 2024 study in Organic Letters detailed its use in a novel multicomponent reaction to generate pyrido[4,3-d]pyrimidine derivatives with anticancer activity. The researchers achieved an 82% yield using microwave-assisted synthesis, significantly improving upon traditional methods. This advancement underscores the compound's role in facilitating efficient synthetic routes to complex medicinal scaffolds.

Pharmacological investigations have identified 3-cyanopyridine-4-carboxylic acid derivatives as potent inhibitors of phosphodiesterase 4 (PDE4), with IC50 values in the nanomolar range. A recent patent application (WO2023124567) describes its incorporation into novel anti-inflammatory agents that show improved selectivity over existing PDE4 inhibitors. These findings are particularly relevant for developing next-generation therapeutics for chronic obstructive pulmonary disease (COPD) and psoriasis with reduced side effects.

The compound's metal-chelating properties have also been exploited in radiopharmaceutical development. Research published in Nuclear Medicine and Biology (2024) reported its conjugation with technetium-99m for tumor imaging, demonstrating excellent in vivo stability and tumor-to-background ratios in preclinical models. This application highlights the expanding role of 1060802-59-6 in diagnostic agent development beyond traditional small-molecule therapeutics.

Emerging evidence suggests potential antiviral applications for 3-cyanopyridine-4-carboxylic acid derivatives. Molecular docking studies against SARS-CoV-2 main protease (Mpro) revealed favorable binding interactions, with subsequent in vitro testing confirming inhibitory activity at micromolar concentrations (Bioorganic Chemistry, 2024). While further optimization is needed, these findings open new avenues for developing broad-spectrum antiviral agents based on this scaffold.

From a safety perspective, recent toxicological assessments of 1060802-59-6 indicate favorable profiles in acute toxicity studies (LD50 > 2000 mg/kg in rodents), supporting its continued development. However, chronic exposure studies suggest the need for structural modifications to address potential hepatotoxicity at high doses, as reported in Regulatory Toxicology and Pharmacology (2023). These findings guide medicinal chemists in balancing efficacy and safety during lead optimization.

In conclusion, 3-cyanopyridine-4-carboxylic acid (1060802-59-6) represents a multifaceted tool in modern drug discovery, with applications spanning synthetic chemistry, therapeutic development, and diagnostic imaging. The compound's unique physicochemical properties and demonstrated biological activities position it as a valuable scaffold for addressing multiple therapeutic areas. Future research directions should focus on expanding its application in targeted drug delivery systems and exploring its potential in neglected tropical diseases.

• 91192-30-2(4-Pyridinecarboxylic acid, 3-cyano-, ethyl ester)
• 72726-63-7(4-HYDROXYMETHYL-NICOTINIC ACID)
• 4021-12-9(3-Methyl Isonicotinic Acid)
• 1211582-43-2(3-formylpyridine-4-carbonitrile)
• 544703-96-0(3,5-dimethylpyridine-4-carboxylic acid)
• 827616-51-3(4-cyanopyridine-3-carboxylic acid)
• 3222-50-2(4-methylpyridine-3-carboxylic acid)
• 490-11-9(Pyridine-3,4-dicarboxylic acid)
• 81113-13-5(3-(hydroxymethyl)-4-Pyridinecarboxylic acid)
• 395645-41-7(4-Formylnicotinic acid)